RSV (Respiratory Syncytial Virus) Vaccine and Antibody Resources for Healthcare Providers | Immunize.org (original) (raw)

Standing Orders for Administering Nirsevimab RSV Preventive Antibody (Beyfortus, by Sanofi) to Infants

Eligible healthcare professionals may vaccinate infants who meet any of the criteria on this form

Standing Orders for Administering Pfizer Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo) During Pregnancy

Eligible healthcare professionals may vaccinate pregnant persons who meet any of the criteria on this form

Standing Orders for Administering Respiratory Syncytial Virus Vaccine (RSV) to Adults Age 60 Years and Older

Eligible healthcare professionals may vaccinate adults age 60 years and older who meet any of the criteria on this form

View all Clinical Resources

Current Recommendations

Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices— United States, 2024

MMWR August 15, 2024 / 73(32);696-702

Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

MMWR, October 13, 2023, 72(41);1115-1122

Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023

MMWR, August 25, 2023, 72(34); 920–925

Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices

MMWR, July 21, 2023, 72 (29); 793-801

Immunization Information Statement (IIS) – Respiratory Syncytial Virus (RSV) Preventive Antibody VIS

Updated: September 25, 2023

RSV (Respiratory Syncytial Virus) Vaccine VIS

Updated: January 31, 2025

This page was updated on June 7, 2024.